Fig. 5

Characterization of therapeutic antitumor effect of CRT/E7(N53S) vaccination against the spontaneous HPV16-E6E7-expressing oral tumor model. A Schematic diagram of the experimental procedure. HPV16-E6E7-expressing oral tumors were induced in HLA-A2 (AAD) transgenic mice (5 per group) as described in Fig. 4. One week after final anti-CD3 injection, tumor bearing mice were then treated with either CRT/E7(N53S) DNA (10 µg/dose/mouse) or empty pcDNA vector (10 µg/dose/mouse) by i.m. injection in the hind leg, followed by electroporation. The mice continued to receive the same vaccination at 4-day intervals 3 additional times. Tumor growth was monitored on days 5, 11, and 18 after the final vaccination. B Bioluminescence imaging of tumor bearing mice treated with CRT/E7(N53S) DNA or empty vector. C Line graph summarizing the luminescent imaging of tumor bearing mice. D Kaplan–Meier survival curve of HPV16-E6E7-expressing oral tumor bearing mice who received CRT/E7(N53S) or empty vector